AI and the digital pathology revolution: clinical applications in cancer diagnosis and assessment.

INTRODUCTION: Hematoxylin & Eosin (H&E) stained slides are the gold standard for cancer diagnosis but are subject to labor-intensive review and inter-observer variability. Whole-slide imaging (WSI) and digital pathology are reshaping this landscape, enabling remote diagnosis, quantitative analysis, and integration with clinical and molecular data for precision medicine. The complexity of cancer diagnosis highlights the need for sophisticated analytical tools capable of extracting multidimensional information from tissue sections. AREAS COVERED: Technological and computational advances driving the integration of artificial intelligence (AI) and digital pathology. The transition from classical machine-learning to deep learning models that automatically learn hierarchical representations from raw WSIs. Convolutional neural networks, transformers and foundational computational pathology models. Tasks such as biomarker prediction and prognostic modeling. Emerging research on multimodal AI systems that are integrating histology images with text data to improve clinical relevance. Challenges related to data sharing and privacy, generalizability, and the implementation of these approaches in real-world clinical settings. Primary keywords used for screening included 'cancer diagnosis,' 'artificial intelligence,' 'digital pathology,' 'regulation,' 'clinical implementation,' 'foundational models,' 'adoption of AI in pathology,' etc and relevant articles from Pubmed and/or company newsletters were used and cited accordingly. EXPERT OPINION: Digital pathology and AI are transforming cancer diagnosis and evaluation. We expect that AI will be increasingly embedded in routine pathology practice to enhance diagnostic accuracy, improve efficiency, advance biological discovery, and perform tasks out of reach of conventional microscopy, thus advancing precision oncology.